Details of the Drug Reposition

General Information of This Drug (ID: DMI9OMV)

Drug Name
NLY01   DMI9OMV
Drug Type
Small molecule

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Parkinson disease DISQVHKL 8A00.0 Phase 2 [1]
Alzheimer disease DISF8S70 8A20 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04154072) Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson's Disease. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Neuraly